Current filters:


Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis


US biotech major Amgen says its Phase III study evaluating the efficacy and safety of its biosimilar…

AbbVieABP 501AmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyDermatologicalsHumiraResearchUSA

Positive new data for AbbVie’s Humira in HS

Positive new data for AbbVie’s Humira in HS


US pharma group AbbVie has released results from a Phase III pivotal study demonstrating that its blockbuster…


Janssen’s guselkumab shows significant efficacy in moderate to severe plaque psoriasis


New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology…

DermatologicalsguselkumabHumiraJanssenJohnson & JohnsonPharmaceuticalResearch

Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study


Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed…

AbbVieAmgenDermatologicalsEnbrelHumiraJanssen BiotechNovartisPharmaceuticalsecukinumabStelara Injectiontofacitinib

Sales of psoriasis drugs to be worth $7.4 billion by 2020


The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Psoriasis drug market expected to double to $6.8 Billion in 2019, driven by biologics penetration and Interleukin/TNF-alpha inhibitors


The continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors, along with a twofold…

BiotechnologyDermatologicalsEnbrelHumiraMarkets & MarketingPharmaceuticalStelara Injection

Back to top